Page 501 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 23 Cancer of the Gastrointestinal Tract 479

84. Vos JP, Burm AGD, Focker BP, et al.: Piroxicam and carboplatin as 105. Yoshikawa H, Ehrhart EJ, Charles JB, et al.: Assessment of pre-
a combination treatment of canine oral non-tonsillar squamous cell dictive molecular variables in feline oral squamous cell carcinoma
carcinoma: a pilot study and a literature review of a canine model treated with stereotactic radiation therapy, Vet Comp Oncol 14:
VetBooks.ir of human head and neck squamous cell carcinoma, Vet Comp Oncol 106. Yoshikawa H, Maranon DG, Battaglia CLR, et al.: Predicting
39–57, 2016.
3:16–24, 2005.
85. Buhles WC, Theilan GH: Preliminary evaluation of bleomycin
in feline and canine squamous cell carcinomas, Am J Vet Res 34: clinical outcome in feline oral squamous cell carcinoma: tumour
initiating cells, telomeres and telomerase, Vet Comp Oncol 14:
289–291, 1973. 371–383, 2016.
86. Bertone ER, Snyder LA, Moore AS, et al.: Environmental and life- 107. Ogilvie GK, Moore AS, Obradovich JE, et al.: Toxicoses and effi-
style risk factors for oral squamous cell carcinoma in domestic cats, cacy associated with administration of mitoxantrone to cats with
J Vet Intern Med 17:557–562, 2003. malignant tumor, J Am Vet Med Assoc 202:1839–1844, 1993.
87. Snyder LA, Bertone ER, Jakowski RM, et al.: p53 expression and 108. Fox LE, Rosenthal RC, King RR, et al.: Use of cis-bis-neodecano-
environmental tobacco smoke exposure in feline oral squamous cell ato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal
carcinoma, Vet Pathol 41:209–214, 2004. cisplatin analogue, in cats with oral squamous cell carcinoma, Am J
88. Martin CK, Tannehill-Gregg SH, Wolfe TD, et al.: Bone- invasive Vet Res 61:791–795, 2000.
oral squamous cell carcinoma in cats: pathology and expres- 109. Hayes A, Scase T, Miller J, et al.: COX-1 and COX-2 expression
sion of parathyroid hormone-related protein, Vet Pathol 48: in feline oral squamous cell carcinoma, J Comp Pathol 135:93–99,
302–312, 2011. 2006.
89. Hutson CA, Willauer CC, Walder EJ, et al.: Treatment of man- 110. DiBernardi L, Dore M, Davis JA, et al.: Study of feline oral squa-
dibular squamous cell carcinoma in cats by use of mandibulectomy mous cell carcinoma: potential target for cyclooxygenase inhibitor
and radiotherapy: seven cases (1987-1989), J Am Vet Med Assoc treatment, Prostaglandins Leukot Essent Fatty Acids 76:245–250,
201:777–781, 1992. 2007.
90. Northrup NC, Selting KA, Rassnick KM, et al.: Outcomes of cats 111. Wiles V, Hohenhaus A, Lamb K, et al.: Retrospective evaluation
with oral tumors treated with mandibulectomy, J Am Anim Hosp of toceranib phosphate (Palladia) in cats with oral squamous cell
Assoc 42:350–360, 2006. carcinoma, J Feline Med Surg 19:185–193, 2017.
91. Reeves NCP, Turrel JM, Withrow SJ: Oral squamous cell carci- 112. Wypij JM, Heller DA: Pamidronate disodium for pallia-
noma in the cat, J Am Anim Hosp Assoc 29:438–441, 1993. tive therapy of feline bone-invasive tumors, Vet Med Int 2014:
92. Bostock DE: The prognosis in cats bearing squamous cell carci- 675172, 2014.
noma, J Small Anim Pract 13:119–125, 1972. 113. Ciekot PA, Powers BE, Withrow SJ, et al.: Histologically low
93. Cotter SM: Oral pharyngeal neoplasms in the cat, J Am Anim Hosp grade yet biologically high grade fibrosarcomas of the mandible
Assoc 17:917–920, 1981. and maxilla of 25 dogs (1982-1991), J Am Vet Med Assoc 204:
94. Hayes AM, Adams VJ, Scase TJ, et al.: Survival of 54 cats with 610–615, 1994.
oral squamous cell carcinoma in United Kingdom general practice, 114. Frazier SA, Johns SM, Ortega J, et al.: Outcome in dogs with sur-
J Small Anim Pract 48:394–399, 2007. gically resected oral fibrosarcoma (1997–2008), Vet Comp Oncol
95. Soltero-Rivera MM, Krick EL, Reiter AM, et al.: Prevalence of 10:33–43, 2011.
regional and distant metastasis in cats with advanced oral squamous 115. Gardner H, Fidel J, Haldorson G, et al.: Canine oral fibrosarcomas:
cell carcinoma: 49 cases (2005–2011), J Feline Med Surg 16:164– a retrospective analysis of 65 cases (1998–2010), Vet Comp Oncol
169, 2014. 13:40–47, 2013.
96. Evans SM, LaCreta F, Helfand S, et al.: Technique, pharmacoki- 116. Thrall DE: Orthovoltage radiotherapy of oral fibrosarcomas in
netics, toxicity, and efficacy of intratumoral etanidazole and radio- dogs, J Am Vet Med Assoc 172:159–162, 1981.
therapy for treatment of spontaneous feline oral squamous cell 117. Forrest LJ, Chun R, Adams WM, et al.: Postoperative radiation
carcinoma, Int J Radiat Oncol Biol Phys 20:703–708, 1991. therapy for canine soft tissue sarcoma, J Vet Intern Med 14:578–
97. LaRue SM, Vail DM, Ogilvie GK, et al.: Shrinking-field radiation 582, 2000.
therapy in combination with mitoxantrone chemotherapy for the 118. Hammer AS, Weeren FR, Weisbrode SE, et al.: Prognostic factors
treatment of oral squamous cell carcinoma in the cat, Vet Cancer Soc in dogs with osteosarcomas of the flat and irregular bones, J Am
Proc 11:99, 1991. Anim Hosp Assoc 31:321–326, 1995.
98. Jones PD, de Lorimier LP, Kitchell BE, et al.: Gemcitabine as a 119. Straw RC, Powers BE, Klausner J, et al.: Canine mandibular osteo-
radiosensitizer for nonresectable feline oral squamous cell carci- sarcoma: 51 cases (1980-1992), J Am Anim Hosp Assoc 32:257–
noma, J Am Anim Hosp Assoc 39:463–467, 2003. 262, 1996.
99. LeBlanc AL, LaDue TA, Turrel JM, et al.: Unexpected toxicity fol- 120. Kazmierski KJ, Dernell WS, Lafferty MH, et al.: Osteosarcoma of
lowing use of gemcitabine as a radiosensitizer in head and neck the canine head: a retrospective study of 60 cases, Vet Cancer Soc
carcinomas: a Veterinary Radiation Therapy Oncology Group pilot Proc 22:30, 2002.
study, Vet Radiol Ultrasound 45:466–470, 2004. 121. Selmic LE, Lafferty MH, Kamstock DA, et al.: Outcome and
100. Fidel JL, Sellon RK, Houston RK, et al.: A nine-day accelerated prognostic factors for osteosarcoma of the maxilla, mandible, or
radiation protocol for feline squamous cell carcinoma, Vet Radiol calvarium in dogs: 183 cases (1986–2012), J Am Vet Med Assoc
Ultrasound 48:482–485, 2007. 245:930–938, 2014.
101. Fidel J, Lyons J, Tripp C, et al.: Treatment of oral squamous cell 122. Coyle VJ, Rassnick KM, Borst LB, et al.: Biological behaviour of
carcinoma with accelerated radiation therapy and concomitant car- canine mandibular osteosarcoma. A retrospective study of 50 cases
boplatin in cats, J Vet Intern Med 25:504–510, 2011. (1999–2007), Vet Comp Oncol 13:89–97, 2015.
102. Bregazzi VS, LaRue SM, Powers BE, et al.: Response of feline oral 123. Fiani N, Vertstraete FJ, Kass PH, et al.: Clinicopathologic charac-
squamous cell carcinoma to palliative radiation therapy, Vet Radiol terization of odontogenic tumors and focal fibrous hyperplasia in
Ultrasound 42:77–79, 2001. dogs: 152 cases (1995-2005), J Am Vet Med Assoc 238:495–500,
103. Poirier VJ, Kaser-Hotz B, Vail DM, et al.: Efficacy and toxicity of an 2011.
accelerated hypofractionated radiation therapy protocol in cats with 124. Dubielzig RR: Proliferative dental and gingival disease of dogs and
oral squamous cell carcinoma, Vet Radiol Ultrasound 54:81–88, 2013. cats, J Am Anim Hosp Assoc 18:577–584, 1982.
104. Sabhlok A, Ayl R: Palliative radiation therapy outcomes for cats 125. Bjorling DE, Chambers JN, Mahaffey EA: Surgical treatment
with oral squamous cell carcinoma (1999–2005), Vet Radiol Ultra- of epulides in dogs: 25 cases (1974-1984), J Am Vet Med Assoc
sound 55:565–570, 2014. 190:1315–1318, 1987.